Researchers reveal integrins could be key to survival mechanism in cancer cells

Cancer cells appear to depend on an unusual survival mechanism to spread around the body, according to an early study led by Queen Mary University of London (QMUL). The discovery could help with future development of novel treatments to prevent metastasis and secondary tumours.

The spread of cancer around the body - metastasis - is one of the biggest challenges in cancer treatment. It is often not the original tumour that kills, but secondary growths. These happen when cancer cells are able to break away from the primary site, travel around the body and 'seed' new tumours.

A key question in cancer research has been how cancer cells are able to survive once they break away from a tumour to spread around the body. Cells are relatively protected when they are attached to other cancer cells and their surroundings, but become more vulnerable when they detach and 'float', and normally undergo cell death.

Lead researcher Dr Stéphanie Kermorgant from QMUL's Barts Cancer Institute said: "Metastasis is currently incurable and remains one of the key targets of cancer research. Our research advances the knowledge of how two key molecules communicate and work together to help cancer cells survive during metastasis. We're hoping that this might lead to the discovery of new drugs to block the spread of cancer within the body."

The study, published in Nature Communications, examined the changes that occur in cancer cells as they break away from tumours in cell cultures, zebrafish and mice. The researchers revealed a previously unknown survival mechanism in cancer cells and found that molecules known as 'integrins' could be key.

Integrins are proteins on the cell surface that attach to and interact with the cell's surroundings. 'Outside-in' and 'inside-out' signalling by integrins is known to help the cancer cells attach themselves to their surroundings. But the study suggests that when the cancer cells are floating, as they do during metastasis, the integrins switch from their adhesion role to take on an entirely new form of communication which has never been seen before - 'inside-in' signalling, in which integrins signal within the cell.

The researchers discovered that an integrin called beta-1 (β1) pairs up with another protein called c-Met and they move inside the cell together. The two proteins then travel to an unexpected location within the cell which is normally used to degrade and recycle cell material. Instead the location is used for a new role of cell communication and the two proteins send a message to the rest of the cell to resist against death while floating during metastasis.

Using both breast and lung cells, the team found that metastases were less likely to form when β1 and c-Met were blocked from entering the cell together or were prevented from moving to the special location within the cell.

Integrins are already major targets for cancer treatment with drugs either being tested or in use in the clinic. Most integrin inhibitor drugs target their adhesive function and block them on the surface of the cancer cell. The researchers say that the limited success of these drugs could be partly explained by this newly discovered role of integrins within the cancer cell.

A new strategy could be to prevent the integrin from going inside the cell in the first place. The researchers hope that these insights could lead to the design of better therapies against metastasis and more effective treatment combinations that could prevent and slow both tumour growth and spread.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Studies link gut dysbiosis to pancreatic cancer, offering pathways for early detection